FibroBiologics (FBLG) Current Leases (2022 - 2026)
FibroBiologics (FBLG) posted quarterly Current Leases of $258000.0 for Q2 2026, down 58.85% year-over-year from $627000.0 in Q2 2025, and down 64.32% on a QoQ basis from $723000.0 in Q1 2026.
FibroBiologics (FBLG) Current Leases (2022 - 2026) Analysis & Trends
FibroBiologics has reported Current Leases for 5 years, with the latest figure at $258000.0 in Q2 2026.
- Current Leases for Q2 2026 came in at $258000.0, down 58.85% year-over-year; the trailing twelve-month figure through Jun 2026 was $258000.0 (down 58.85% YoY), and the FY2025 annual result was $706000.0, up 76.06% from the prior year.
- Current Leases declined to $258000.0 in Q2 2026, from $723000.0 in the prior quarter.
- Over five years, Current Leases peaked at $723000.0 in Q1 2026 and troughed at $258000.0 in Q2 2026.
- A 5-year average of $467000.0 and a median of $396500.0 in 2024 frame the typical range for Current Leases.
- The widest annual swing landed in 2025, when Current Leases surged 76.06%; it then slumped 58.85% in 2026.
- A 5-year view of Current Leases shows it stood at $326000.0 in 2022, then rose by 11.04% to $362000.0 in 2023, then advanced by 10.77% to $401000.0 in 2024, then surged by 76.06% to $706000.0 in 2025, then plunged by 63.46% to $258000.0 in 2026.
- Per Business Quant data, the three most recent Current Leases figures were $258000.0 in Q2 2026, $723000.0 in Q1 2026, and $706000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | - |
| 10 | FibroBiologics | 8.91 Mn | 8.91 Mn | - | 258,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 258,000.00 |
| Mar 31, 2026 | 723,000.00 |
| Dec 31, 2025 | 706,000.00 |
| Sep 30, 2025 | 643,000.00 |
| Jun 30, 2025 | 627,000.00 |
| Mar 31, 2025 | 412,000.00 |
| Dec 31, 2024 | 401,000.00 |
| Sep 30, 2024 | 392,000.00 |
| Jun 30, 2024 | 382,000.00 |
| Mar 31, 2024 | 372,000.00 |
| Dec 31, 2023 | 362,000.00 |
| Dec 31, 2022 | 326,000.00 |